DK3430397T3 - Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner - Google Patents
Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner Download PDFInfo
- Publication number
- DK3430397T3 DK3430397T3 DK17711134.1T DK17711134T DK3430397T3 DK 3430397 T3 DK3430397 T3 DK 3430397T3 DK 17711134 T DK17711134 T DK 17711134T DK 3430397 T3 DK3430397 T3 DK 3430397T3
- Authority
- DK
- Denmark
- Prior art keywords
- ingregation
- phagocytose
- mediated
- antibody
- assay
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Ecology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662308082P | 2016-03-14 | 2016-03-14 | |
PCT/EP2017/056031 WO2017157961A1 (en) | 2016-03-14 | 2017-03-14 | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3430397T3 true DK3430397T3 (da) | 2022-05-02 |
Family
ID=58347346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17711134.1T DK3430397T3 (da) | 2016-03-14 | 2017-03-14 | Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner |
Country Status (6)
Country | Link |
---|---|
US (1) | US11340225B2 (da) |
EP (2) | EP3430397B1 (da) |
DK (1) | DK3430397T3 (da) |
MA (1) | MA43723A (da) |
PL (1) | PL3430397T3 (da) |
WO (1) | WO2017157961A1 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
EP3430397B1 (en) | 2016-03-14 | 2022-02-23 | Biogen International Neuroscience GmbH | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル-マイヤーズ スクイブ カンパニー | アルファ-シヌクレインに対する抗体およびその使用 |
SI3672631T1 (sl) | 2017-08-22 | 2023-06-30 | Biogen Ma Inc. | Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu |
CN112601550B (zh) * | 2018-05-30 | 2023-12-08 | 财团法人卫生研究院 | 抗-乙型淀粉样蛋白抗体及其用途 |
EP3956664A1 (en) * | 2019-04-18 | 2022-02-23 | Genentech, Inc. | Antibody potency assay |
CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
JP2024505600A (ja) | 2021-02-03 | 2024-02-06 | モーツァルト セラピューティクス, インコーポレイテッド | 結合剤およびそれを使用する方法 |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
TW202308699A (zh) | 2021-04-23 | 2023-03-01 | 美商普方生物製藥美國公司 | Cd70結合劑、其結合物及其使用方法 |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
US12084492B2 (en) | 2023-01-20 | 2024-09-10 | Mabwell Therapeutics, Inc. | Anti-amyloid beta protofibril/oligomer antibodies and uses thereof |
WO2024243423A1 (en) | 2023-05-24 | 2024-11-28 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
WO2025072406A1 (en) | 2023-09-26 | 2025-04-03 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
WO2025117639A1 (en) | 2023-11-27 | 2025-06-05 | Profoundbio Us Co. | Antibodies and methods for ptk7 detection |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030028904A1 (en) | 2001-04-19 | 2003-02-06 | Gumienny Tina L. | Genes involved in engulfment of dying cells and cell migration |
CN101622275B (zh) * | 2007-01-05 | 2013-11-06 | 苏黎世大学 | 提供疾患特异性结合分子和靶的方法 |
US7771957B2 (en) | 2007-10-19 | 2010-08-10 | The Regents Of The University Of California | Method for diagnosing alzheimer's disease |
BRPI0923157B1 (pt) | 2008-12-19 | 2021-12-28 | University Of Zürich | Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática |
DK2627672T3 (da) | 2010-10-11 | 2018-08-27 | Biogen Idec Int Neuroscience Gmbh | Humane anti-tau antistoffer |
TR201815563T4 (tr) | 2011-06-23 | 2018-11-21 | Biogen Int Neuroscience Gmbh | Anti-alfa sinüklein bağlayıcı moleküller. |
GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
MY167795A (en) | 2011-10-28 | 2018-09-26 | Biogen Int Neuroscience Gmbh | Tdp-43 specefic binding molecules |
LT2935326T (lt) | 2012-12-21 | 2020-12-10 | Biogen Ma Inc. | Žmogaus antikūnai prieš tau baltymą |
CN116396393A (zh) * | 2015-10-08 | 2023-07-07 | 酵活英属哥伦比亚省公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
EP3430397B1 (en) | 2016-03-14 | 2022-02-23 | Biogen International Neuroscience GmbH | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
-
2017
- 2017-03-14 EP EP17711134.1A patent/EP3430397B1/en active Active
- 2017-03-14 PL PL17711134T patent/PL3430397T3/pl unknown
- 2017-03-14 MA MA043723A patent/MA43723A/fr unknown
- 2017-03-14 EP EP22157536.8A patent/EP4063858A1/en active Pending
- 2017-03-14 WO PCT/EP2017/056031 patent/WO2017157961A1/en active Application Filing
- 2017-03-14 DK DK17711134.1T patent/DK3430397T3/da active
- 2017-03-14 US US16/083,695 patent/US11340225B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MA43723A (fr) | 2021-05-19 |
EP3430397B1 (en) | 2022-02-23 |
US11340225B2 (en) | 2022-05-24 |
EP4063858A1 (en) | 2022-09-28 |
WO2017157961A1 (en) | 2017-09-21 |
PL3430397T3 (pl) | 2022-04-04 |
EP3430397A1 (en) | 2019-01-23 |
US20190079077A1 (en) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3430397T3 (da) | Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner | |
IL272466A (en) | Antigen-binding proteins targeting shared antigens | |
EP3562391A4 (en) | Patch for temperature determination | |
DK3554681T3 (da) | Fremgangsmåde til proteincorona-sensorarray til tidlig detektering af sygdomme | |
DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
IL256643A (en) | Immune checkpoint chimeric antigen receptors therapy | |
IL254276B (en) | Chimeric antigen receptors targeting b-cell maturation antigen | |
DK3332006T3 (da) | Hidtil ukendte anti-PD-L1-antistoffer | |
DK3313874T3 (da) | Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering | |
DK3294764T3 (da) | Kimæriske antigenreceptor sammensætninger | |
EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
DK3563156T3 (da) | Fremgangsmåde til separering af biomolekyler | |
HUE047929T2 (hu) | Kiméra antigén receptor | |
DK3310809T3 (da) | Anti-cgrp-antistofformulering | |
DK3473783T3 (da) | Fremgangsmåde til fremstilling af gulvplader | |
DK3440703T3 (da) | Waferskalaenhed til isolator-membran-isolatoranordninger til nanoporemåling | |
DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
DK3287523T3 (da) | Fremgangsmåde til sekretorisk fremstilling af protein | |
EP3191599C0 (en) | DETECTION OF MISFOLDED PROTEINS | |
DK3334457T3 (da) | Humaniserede anti-CCR7-receptorantistoffer | |
DK3014279T3 (da) | Fremgangsmåde til bestemmelse af proteinaggregater under anvendelse af overflade-fida | |
DK3464331T3 (da) | Stabiliserede præfusions-rsv f-proteiner | |
DK3713928T3 (da) | Hidtil ukendte bradykinin-b2-receptorantagonister | |
IL282114A (en) | Processes for preparing functionalized cyclooctenes |